This study was designed to test the central hypothesis that combined ALA and metformin therapy provides synergistic neuroprotection in diabetic encephalopathy through enhanced co-activation of Nrf2 and AMPK signaling cascades, leading to superior mitochondrial function restoration, comprehensive antioxidant defense enhancement, and meaningful cognitive improvement compared to individual treatments. This evidence concerns the gene NFE2L2 and diabetic encephalopathy.